These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28013578)

  • 1. Molecular docking, synthesis, and biological evaluation of naphthoquinone as potential novel scaffold for H5N1 neuraminidase inhibition.
    Sharma G; Vasanth Kumar S; Wahab HA
    J Biomol Struct Dyn; 2018 Jan; 36(1):233-242. PubMed ID: 28013578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
    Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W
    J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.
    Chintakrindi AS; Martis EA; Gohil DJ; Kothari ST; Chowdhary AS; Coutinho EC; Kanyalkar MA
    Curr Comput Aided Drug Des; 2016; 12(4):272-281. PubMed ID: 27412704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors.
    Lin X; Qin-Hua C; Peng L; Chun-Lei L; Guang-De Y
    Chem Biol Drug Des; 2018 Jan; 91(1):105-115. PubMed ID: 28646621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
    D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L
    Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
    Park JW; Jo WH
    Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design.
    Gong K; Li L; Wang JF; Cheng F; Wei DQ; Chou KC
    Med Chem; 2009 May; 5(3):242-9. PubMed ID: 19442214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
    Wang Z; Cheng LP; Zhang XH; Pang W; Li L; Zhao JL
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5429-5435. PubMed ID: 29141777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.
    Wang P; Zhang JZ
    J Phys Chem B; 2010 Oct; 114(40):12958-64. PubMed ID: 20860351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
    Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
    Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach.
    Karthick V; Ramanathan K; Shanthi V; Rajasekaran R
    Cell Biochem Biophys; 2013 Jul; 66(3):657-69. PubMed ID: 23306969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold.
    Colombo C; Pinto BM; Bernardi A; Bennet AJ
    Org Biomol Chem; 2016 Jul; 14(27):6539-53. PubMed ID: 27305457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel binding patterns between ganoderic acids and neuraminidase: Insights from docking, molecular dynamics and MM/PBSA studies.
    Yang Z; Wu F; Yuan X; Zhang L; Zhang S
    J Mol Graph Model; 2016 Apr; 65():27-34. PubMed ID: 26905206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase.
    Colombo C; Podlipnik Č; Lo Presti L; Niikura M; Bennet AJ; Bernardi A
    PLoS One; 2018; 13(2):e0193623. PubMed ID: 29489903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
    Wang B; Wang K; Meng P; Hu Y; Yang F; Liu K; Lei Z; Chen B; Tian Y
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3477-3482. PubMed ID: 30266543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexity in influenza virus targeted drug design: interaction with human sialidases.
    Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
    J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.